Mobile

Open-Label, Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Combination with Sofosbuvir and Ribavirin in Chronic Hepatitis C (HCV) Infected Subjects Who Have Experienced Virologic Fai...

Mise à jour : Il y a 4 ans
Référence : EUCTR2016-002491-26

Open-Label, Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Combination with Sofosbuvir and Ribavirin in Chronic Hepatitis C (HCV) Infected Subjects Who Have Experienced Virologic Failure in AbbVie HCV Clinical Studies

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

The primary objectives of this study are to assess the efficacy by evaluating the percentage of subjects achieving a 12-week post-treatment sustained virologic failure response (SVR12) in each treatment arm and safety of ABT-493/ABT-530 plus SOF and RBV in adults with chronic HCV GT1-6 infection who previously failed HCV treatment in an AbbVie HCV clinical study, designated as an AbbVie HCV parent study.

Critère d'inclusion

  • Chronic Hepatitis C Infection

Liens